Academic literature on the topic 'TOR Serine-Threonine Kinases'

The TOR (target of rapamycin) serine/threonine kinases are fascinating in that they influence many different aspects of eukaryote physiology including processes often dysregulated in disease. Beginning with the initial characterization of rapamycin as an antifungal agent, studies with yeast have contributed greatly to our understanding of the molecular pathways in which TORs operate. Recently, building on advances in quantitative MS, the rapamycin-dependent phosphoproteome in the budding yeast Saccharomyces cerevisiae was elucidated. These studies emphasize the central importance of TOR and highlight its many previously unrecognized functions. One of these, the regulation of intermediary metabolism, is discussed.

STK16 (Ser/Thr kinase 16, also known as Krct/PKL12/MPSK1/TSF-1) is a myristoylated and palmitoylated Ser/Thr protein kinase that is ubiquitously expressed and conserved among all eukaryotes. STK16 is distantly related to the other kinases and belongs to the NAK kinase family that has an atypical activation loop architecture. As a membrane-associated protein that is primarily localized to the Golgi, STK16 has been shown to participate in the TGF-β signaling pathway, TGN protein secretion and sorting, as well as cell cycle and Golgi assembly regulation. This review aims to provide a comprehensive summary of the progress made in recent research about STK16, ranging from its distribution, molecular characterization, post-translational modification (fatty acylation and phosphorylation), interactors (GlcNAcK/DRG1/MAL2/Actin/WDR1), and related functions. As a relatively underexplored kinase, more studies are encouraged to unravel its regulation mechanisms and cellular functions.

ABSTRACT Pseudomonas aeruginosa is an opportunistic pathogen that causes infections in eye, urinary tract, burn, and immunocompromised patients. We have cloned and characterized a serine/threonine (Ser/Thr) kinase and its cognate phosphoprotein phosphatase. By using oligonucleotides from the conserved regions of Ser/Thr kinases of mycobacteria, an 800-bp probe was used to screenP. aeruginosa PAO1 genomic library. A 20-kb cosmid clone was isolated, from which a 4.5-kb DNA with two open reading frames (ORFs) were subcloned. ORF1 was shown to encode Ser/Thr phosphatase (Stp1), which belongs to the PP2C family of phosphatases. Overlapping with the stp1 ORF, an ORF encoding Hank’s type Ser/Thr kinase was identified. Both ORFs were cloned in pGEX-4T1 and expressed in Escherichia coli. The overexpressed proteins were purified by glutathione-Sepharose 4B affinity chromatography and were biochemically characterized. The Stk1 kinase is 39 kDa and undergoes autophosphorylation and can phosphorylate eukaryotic histone H1. A site-directed Stk1 (K86A) mutant was shown to be incapable of autophosphorylation. A two-dimensional phosphoamino acid analysis of Stk1 revealed strong phosphorylation at a threonine residue and weak phosphorylation at a serine residue. The Stp1 phosphatase is 27 kDa and is an Mn2+-, but not a Ca2+- or a Mg2+-, dependent Ser/Thr phosphatase. Its activity is inhibited by EDTA and NaF, but not by okadaic acid, and is similar to that of PP2C phosphatase.

cAMP-dependent protein kinase (PKA) is the major receptor of the second messenger cAMP and a prototype for Ser/Thr-specific protein kinases. Although PKA strongly prefers serine over threonine substrates, little is known about the molecular basis of this substrate specificity. We employ classical enzyme kinetics and a surface plasmon resonance (SPR)-based method to analyze each step of the kinase reaction. In the absence of divalent metal ions and nucleotides, PKA binds serine (PKS) and threonine (PKT) substrates, derived from the heat-stable protein kinase inhibitor (PKI), with similar affinities. However, in the presence of metal ions and adenine nucleotides, the Michaelis complex for PKT is unstable. PKA phosphorylates PKT with a higher turnover due to a faster dissociation of the product complex. Thus, threonine substrates are not necessarily poor substrates of PKA. Mutation of the DFG+1 phenylalanine to β-branched amino acids increases the catalytic efficiency of PKA for a threonine peptide substrate up to 200-fold. The PKA Cα mutant F187V forms a stable Michaelis complex with PKT and shows no preference for serine versus threonine substrates. Disease-associated mutations of the DFG+1 position in other protein kinases underline the importance of substrate specificity for keeping signaling pathways segregated and precisely regulated.

Calmodulin is phosphorylated in vitro by the insulin-receptor tyrosine kinase and a variety of serine/threonine kinases. Here we report that insulin stimulates the phosphorylation of calmodulin on average 3-fold in intact rat hepatocytes. Although calmodulin is constitutively phosphorylated, insulin increases phosphate incorporation into serine, threonine and tyrosine residues. We demonstrate that casein kinase II, an insulin-sensitive kinase, phosphorylates calmodulin in vitro on serine/thyronine residues (Thr-79, Ser-81, Ser-101 and Thr-117). The ability of the insulin receptor to phosphorylate calmodulin that has been pre-phosphorylated by casein kinase II is enhanced up to 35-fold, and the sites of phosphorylation on calmodulin are shifted from tyrosine to threonine and serine. These observations, obtained with a new specific monoclonal antibody to calmodulin, confirm that insulin stimulates calmodulin phosphorylation in intact cells. The observation that calmodulin is phosphorylated in vivo, coupled with the recent demonstration that phosphocalmodulin exhibits altered biological activity, strongly suggests that phosphorylation of calmodulin is a critical component of intracellular signalling.

We have recently reported that Ser/Thr phosphatases play a key role in regulating natural killer (NK) cell lytic activity and that calyculin A and okadaic acid affect this activity differently [Bajpai and Brahmi (1994) J. Biol. Chem. 269, 18864–18869]. Here, we investigate a mechanism that might account for this differential action of calyculin A and okadaic acid on NK cells. Calyculin A specifically inhibited the lytic activity of YT-INDY, an NK-like cell line, and hyperphosphorylated 60 and 78 kDa proteins. The kinetics of appearance of these two proteins was correlated with the loss of lytic activity. In contrast, okadaic acid did not significantly affect either of these activities. The 78 kDa protein is localized in the cytosolic compartment whereas the 60 kDa protein is distributed equally between the membrane and the cytosolic fractions. Both proteins display a kinase activity and are phosphorylated mainly at serine and threonine residues but not at tyrosine residues. The activation of these kinases is specific to calyculin A treatment; it is independent of protein kinase C, protein kinase A, Ca2+, phosphotyrosine phosphatase and protein synthesis de novo. In conclusion, we have demonstrated that calyculin A, but not okadaic acid, hyperphosphorylates two proteins with Ser/Thr kinase activity, thus explaining the differential regulation of NK cells by these two Ser/Thr phosphatase inhibitors.

ABSTRACT A 4.2-kb SphI-BamHI fragment of chromosomal DNA from Streptomyces granaticolor was cloned and shown to encode a protein with significant sequence similarity to the eukaryotic protein serine/threonine kinases. It consists of 701 amino acids and in the N-terminal part contains all conserved catalytic domains of protein kinases. The C-terminal domain of Pkg2 contains seven tandem repeats of 11 or 12 amino acids with similarity to the tryptophan-docking motif known to stabilize a symmetrical three-dimensional structure called a propeller structure. The pkg2 gene was overexpressed inEscherichia coli, and the gene product (Pkg2) has been found to be autophosphorylated at serine and threonine residues. The N- and C-terminal parts of Pkg2 are separated with a hydrophobic stretch of 21 amino acids which translocated a PhoA fusion protein into the periplasm. Thus, Pkg2 is the first transmembrane protein serine/threonine kinase described for streptomycetes. Replacement of the pkg2 gene by the spectinomycin resistance gene resulted in changes in the morphology of aerial hyphae.

ABSTRACT PknB is a member of the newly discovered eukaryotic-like protein serine/threonine kinase (PSTK) family of proteins. The pknBgene was cloned and expressed in Escherichia coli. The active recombinant protein was purified and shown to be reactive with antiphosphoserine antibodies, as well as with antibodies to the phosphorylated eukaryotic Ser/Thr kinases mitogen-activated protein kinase kinase 3 and 6, P38, and Creb. In vitro kinase assays demonstrated that PknB is a functional kinase that is autophosphorylated on serine/threonine residues and is also able to phosphorylate the peptide substrate myelin basic protein. Analysis ofpknB expression in Mycobacterium tuberculosisindicates the presence of pknB mRNA in (i) organisms grown in vitro in bacteriological media, (ii) a murine macrophage in vitro infection model, and (iii) in vivo alveolar macrophages from a patient with tuberculosis.

We have developed a method to study the primary sequence specificities of protein kinases by using an oriented degenerate peptide library. We report here the substrate specificities of eight protein Ser/Thr kinases. All of the kinases studied selected distinct optimal substrates. The identified substrate specificities of these kinases, together with known crystal structures of protein kinase A, CDK2, Erk2, twitchin, and casein kinase I, provide a structural basis for the substrate recognition of protein Ser/Thr kinases. In particular, the specific selection of amino acids at the +1 and -3 positions to the substrate serine/threonine can be rationalized on the basis of sequences of protein kinases. The identification of optimal peptide substrates of CDK5, casein kinases I and II, NIMA, calmodulin-dependent kinases, Erk1, and phosphorylase kinase makes it possible to predict the potential in vivo targets of these kinases.

Orientadores: Sandra Martha Gomes Dias, Marília Meira Dias
Dissertação (mestrado) - Universidade Estadual de Campinas, Instituto de Biologia
Made available in DSpace on 2018-08-24T09:41:29Z (GMT). No. of bitstreams: 1 Ascencao_CarollineFernandaRodrigues_M.pdf: 4713312 bytes, checksum: b65183d96535d66661af745a562f2d58 (MD5) Previous issue date: 2014
Resumo: A proliferação celular comanda os processos de embriogênese e de crescimento do organismo, sendo essencial para a correta função de vários tecidos adultos. Apesar de ser importante para a homeostase do organismo, a sua desregulação compõe a força motriz do desenvolvimento tumoral. Somente nos últimos vinte anos começou a ser evidenciada a relação entre as vias de tradução de sinais estimuladas por fatores de crescimento e a reorganização da atividade metabólica, a qual precisa priorizar a biossíntese e o aumento da biomassa, processos essenciais para a divisão celular. Em células tumorais, o consumo de glutamina é aumentando concomitante ao aumento da atividade de glutaminase. Três isoenzimas de glutaminase são expressas na maioria dos tecidos (liver-type glutaminase, kidney-type glutaminase e glutaminase C), todavia pouco se sabe sobre a necessidade específica de cada uma delas para o metabolismo tumoral. Vários artigos recentes têm definido o papel da glutaminólise, ou metabolismo da glutamina e seus subprodutos, na ativação da mTOR. Neste sentido é uma hipótese válida imaginar que mTOR possa contra-regular glutaminase. Desta maneira, resolvemos investigar se mTOR atua na regulação da atividade de glutaminase. Para tanto, realizamos knockdown estável de PTEN em células MDA-MB 231 e verificamos que não o mesmo afetou os níveis protéicos de GAC e KGA, assim como não houve mudança na localização subcelular das isoformas. Cinética enzimática da fração mitocondrial desta linhagem revelou que o knockdown de PTEN levou à uma diminuição do KM da enzima sem alteração de Vmax. De acordo, o tratamento com rapamicina, inibidor da mTOR, elevou o KM para os níveis detectados nas células controles. A atividade de glutaminase de lisado total de MDA-MB 231, NIH 3T3, IMR90 e BJ5TA foi afetada pelo tratamento com rapamicina conforme julgado por ensaios de dose e tempo resposta. Mais, ensaios de privação de glicose, glutamina e de fatores de crescimento levaram à inibição de mTOR e concomitante redução da atividade de glutaminase. Somado a isso, o knockdown estável de TSC2 em MDA-MB 231 e BJ5TA, assim como o knockout de TSC2 em MEF, promoveu superestimulação de mTOR e foi capaz de aumentar a atividade de glutaminase. Dosagem de atividade de glutaminase de células MDA-MB 231 com knockdown de GAC, KGA ou GAC/KGA tratadas com rapamicina indicaram que mTOR possa agir em ambas as isoformas. Curioso foi que apenas células shGAC e shGAC/KGA apresentaram redução da fosforilação de S6K em Thr389 indicando que GAC ou o metabolismo de glutamina via esta isoforma, possa contra-regular mTOR. Em adição, na comparação entre PC3 e DU145, verificamos que DU145 apresentou maior expressão de GAC, maior consumo de glutamina, maior dependência de glutamina em seu crescimento, maior sensibilidade ao inibidor de glutaminase, BPTES, e por fim, se mostrou mais responsiva à metformina, ativador indireto de AMPK. A ativação de AMPK por metformina, um conhecido sensor de estresse energético, mostrou diminuir a atividade de glutaminase em célula de tumor de próstata, DU145, indicando uma potencial ação de AMPK na atividade de glutaminase
Abstract: Cell proliferation is crucial for embryogenesis and organism growth, being also essential for the proper function of several adult tissues. Although important for the homeostasis of the organism, its deregulation composes the driving force of tumor development. In the past twenty years the relationship between the processes of signal translation stimulated by growth factors and the reorganization of metabolic activity has become more evident. Growing cells need to prioritize the biosynthesis and biomass increase, processes essential for cell division. In tumor cells, the glutamine consumption is increased concurrently with the increasing in the glutaminase activity. Three glutaminase isoenzymes are expressed in most tissues (liver- type glutaminase, kidney -type glutaminase and glutaminase C), but not much is known about the necessity of each isoform for the tumor metabolism. Several recent papers have defined the role of glutaminolysis or glutamine metabolism in mTOR activation. So it is a valid hypothesis to speculate that mTOR can counter-regulate glutaminase. Thus, we decided to investigate whether mTOR can control glutaminase activity. To this end, we have made MDA - MB 231 cells stably knocked down for PTEN and verified no alteration in KGA and GAC protein levels, as well as there was no change on their subcellular location. Enzyme kinetics of the MDA-MB 231 mitochondrial fraction revealed that PTEN knockdown led to a decrease in the KM of the enzyme without changing Vmax. Accordingly, the treatment with rapamycin (mTOR inhibitor), led to an increase in KM back to the level detected in control cells. The glutaminase activity of MDA - MB 231, NIH 3T3, IMR90 and BJ5TA total cellular lysates was also affected by rapamycin treatment in a dose- and time-response fashion. Moreover, glucose, glutamine and growth factors deprivation promoted mTOR inhibition and concomitant reduction on glutaminase activity. Glutaminase activity of MDA-MB 231 cells knocked down for GAC, KGA or GAC/KGA and treated with rapamycin indicated that mTOR can regulate both isoforms. Curiously, it was only on GAC or GAC/KGA knocked down cells that we observed a decrease in S6K Thr 389 phosphorylation, which could indicate that GAC or the GAC dependent-glutamine metabolism is a specific mTOR counter-regulator. Accordling, stable TSC2 knockdown in MDA-MB 231 and BJ5TA, as well as TCS2 knockout in MEF cells, promoted overstimulation of mTOR and increasing on glutaminase activity. Moreover, a comparison between PC3 and DU145 revealed that DU145 has higher GAC expression, greater consumption of glutamine, is more dependent on glutamine for its growth, more sensitive to the inhibitor of glutaminase, BPTES, and more responsive to metformin, an indirect AMPK activator. The activation of AMPK by metformin, a known energy stress sensor, led to a decreased glutaminase activity in the prostate tumor cell line DU145 indicating a potential role of AMPK on glutaminase activity
Mestrado
Genetica Animal e Evolução
Mestra em Genética e Biologia Molecular

Orientador: Gonçalo Amarante Guimarães Pereira
Dissertação (mestrado) - Universidade Estadual de Campinas, Instituto de Biologia
Made available in DSpace on 2018-08-21T15:05:51Z (GMT). No. of bitstreams: 1 Almeida_GustavoPereirade_M.pdf: 7665145 bytes, checksum: 3fef8dc5d333834f8117015fea3b10ef (MD5) Previous issue date: 2012
Resumo: A produção de energia por meio de fontes renováveis é uma exigência atual para se atingir uma economia sustentável. Os organismos fotossintetizantes surgem nesse contexto como ferramentas importantes na produção de compostos carbônicos ricos em energia, com destaque para microalgas em que tais compostos podem atingir até 80% do peso seco. Entretanto, um fator ainda desfavorável para sua utilização é o seu baixo rendimento na produção de biomassa. A espécie Chlamydomonas reinhardtii, por exemplo, é capaz de duplicar apenas algumas vezes durante 24 horas. As vias que controlam o crescimento celular, portanto, são alvos promissores para modificação genética. Dentre essas vias, à via de sinalização sensível à rapamicina aparece como um controlador central. Com o intuito de entender melhor como esse controle é exercido ao nível da expressão gênica global, foi utilizado a ferramenta de sequenciamento de RNA em larga escala para obtenção dos transcriptomas de culturas (sincronizadas) sob inibição dessa via e na condição controle, em oito momentos ao longo de um ciclo celular de 24h. O controle exercido por essa via sobre o metabolismo e sobre o ciclo celular foi o foco das análises. Foi encontrado que a inibição da via da TOR é capaz de gerar uma resposta de direcionamento parcial do metabolismo para a produção de TAG em detrimento de moléculas complexas como proteínas. Esse direcionamento foi considerado parcial devido à ocorrência concomitante de reações catabólicas. Outros dados obtidos sugerem que a via da TOR, além de regular o metabolismo de uma maneira geral e diversas funções celulares, também exerce influência sobre o progresso do ciclo celular e sua inibição resulta no atraso do desenvolvimento das fases do ciclo. Diversos fatores reguladores da transcrição envolvidos no desenvolvimento, no crescimento e na regulação do ciclo celular, foram encontrados diferencialmente expressos e constituem possíveis genes chave no controle do crescimento. Eles representam alvos em potencial para modificação genética com intuito de otimizar as taxas de crescimento na primeira etapa do sistema de produção. Na busca de alternativas aos processos atuais de indução do acúmulo de cadeias carbônicas, os efeitos da combinação rapamicina e via da TOR representam uma abordagem interessante para pesquisas futuras para viabilização da utilização de microalgas como fonte de energia. Este estudo possibilitou um melhor entendimento da atuação da via da TOR no crescimento e progresso do ciclo celular em C. reinhardtii ao nível de expressão gênica
Abstract: The energy production through renewable sources is an actual demand for achieving a sustainable economy. In this context, photosynthesizing organisms come to light as important tools for the production of energy-rich carbonic compounds, especially the microalgae, in which these compounds can reach up to 80% of the dry weight. However, an unfavorable factor for its utilization is the low yield of biomass production. The species Chlamydomonas reinhardtii, for instance, is capable of achieving only some duplication after 24 hours. The pathways that control cell growth are therefore promising targets for genetic modification. Among them, the rapamycin-sensitive signaling pathway emerges as a central controller. With the aim of better understanding how this control is fulfilled by the means of global gene expression, the high throughput RNA sequencing technology was used. With it, the synchronized cultures transcriptome under the inhibition of this pathway and in the control condition, of eight points during a cellular cycle of 24 hours, were obtained. The metabolism and the cell cycle control by the TOR pathway was the main focus of the analysis. It was found that the inhibition of this pathway is capable to partially draw the metabolism towards TAG production to the detriment of producing more complex chains as proteins. This directing was considered partial due to the concomitant occurrence of catabolic reactions. Other data suggested that the TOR pathway, apart from the metabolism regulation in a general way and regulation of many other cellular functions, also influence the cell cycle progression and its inhibition retards the development of cell phases. Several transcription regulators involved in development, growth and cell cycle regulation were found out to be differentially expressed and are likely to constitute key genes in growth control. They represent potential targets for genetic modification aiming the optimization of growth rate in the first step of the production system. In the search for alternatives to the current process of inducing carbon chain accumulation, the effects of the combination between rapamycin and TOR pathway represent an interesting approach for future research intending to turn the utilization of microalgae as an energy source into a feasible option. This study enabled a better understanding of the role of the TOR pathway in growth and cell cycle progression of C. reinhardtii at the level of gene expression
Mestrado
Genetica de Microorganismos
Mestre em Genética e Biologia Molecular

Pancreatic ductal adenocarcinoma (PDAC), the most common form of pancreatic cancer, develops through progression of premalignant pancreatic intraepithelial neoplasias (PanINs). In mouse-models, KRAS-activation in acinar cells induced an acinar-to-ductal metaplasia (ADM), and mutation of the Kras oncogene is believed to initiate PanIN formation. ADM is also promoted by pancreatic injury, which cooperates with activated KRAS to stimulate PanIN and PDAC formation from metaplastic ducts. Our lab, and others, have shown that the downstream PI3K/AKT pathway is important for KRAS-mediated proliferation and survival in vitro and in vivo. Prior studies have demonstrated that full activation of AKT requires both PDK1- mediated phosphorylation of AKTT308 and mTOR complex 2 (mTORC2)-mediated phosphorylation of AKTS473. Given the importance of the PI3K/AKT signaling axis, I hypothesized that mTORC2 is required for KRAS-driven pancreatic tumorigenesis and investigated this relationship in mice by combining pancreasspecific expression of an activated KRASG12D molecule with deletion of the essential mTORC2 subunit RICTOR. In the context of activated KRAS, Rictor-null pancreata developed fewer PanIN lesions; these lesions lacked mTORC2 signaling and their proliferation and progression were impaired. Higher levels of nuclear cyclin dependent kinase inhibitors (CDKIs) were maintained in Rictor-null lesions, and nuclear BMI1, a known regulator of the CDKI Cdkn2a, inversely correlated with their expression.Rictor was not required for KRAS-driven ADM following acute pancreatitis, however the inverse correlation between CDKIs and BMI1 was maintained in this system. Treatment of PDX-Cre;KRASG12D/+;Trp53R172H/+ mice with an mTORC1/2 inhibitor delayed tumor formation, and prolonged the survival of mice with late stage PDAC. Knockdown of Rictor in established PDAC cell lines impaired proliferation and anchorage independent growth supporting a role for mTORC2 in fully transformed cells. These data suggest that mTORC2 cooperates with activated KRAS in the initiation and progression of PanIN lesions and is required for the transformation and maintenance of PDAC. My work illustrates phenotypic differences between pancreatic loss of Rictor and PDK1 in the context of KRAS, broadens our understanding of this signaling node and suggests that mTORC2 may potentially be a viable target for PDAC therapies.

Pancreatic ductal adenocarcinoma (PDAC), the most common form of pancreatic cancer, develops through progression of premalignant pancreatic intraepithelial neoplasias (PanINs). In mouse-models, KRAS-activation in acinar cells induced an acinar-to-ductal metaplasia (ADM), and mutation of the Kras oncogene is believed to initiate PanIN formation. ADM is also promoted by pancreatic injury, which cooperates with activated KRAS to stimulate PanIN and PDAC formation from metaplastic ducts. Our lab, and others, have shown that the downstream PI3K/AKT pathway is important for KRAS-mediated proliferation and survival in vitro and in vivo. Prior studies have demonstrated that full activation of AKT requires both PDK1- mediated phosphorylation of AKTT308 and mTOR complex 2 (mTORC2)-mediated phosphorylation of AKTS473. Given the importance of the PI3K/AKT signaling axis, I hypothesized that mTORC2 is required for KRAS-driven pancreatic tumorigenesis and investigated this relationship in mice by combining pancreasspecific expression of an activated KRASG12D molecule with deletion of the essential mTORC2 subunit RICTOR. In the context of activated KRAS, Rictor-null pancreata developed fewer PanIN lesions; these lesions lacked mTORC2 signaling and their proliferation and progression were impaired. Higher levels of nuclear cyclin dependent kinase inhibitors (CDKIs) were maintained in Rictor-null lesions, and nuclear BMI1, a known regulator of the CDKI Cdkn2a, inversely correlated with their expression.Rictor was not required for KRAS-driven ADM following acute pancreatitis, however the inverse correlation between CDKIs and BMI1 was maintained in this system. Treatment of PDX-Cre;KRASG12D/+;Trp53R172H/+ mice with an mTORC1/2 inhibitor delayed tumor formation, and prolonged the survival of mice with late stage PDAC. Knockdown of Rictor in established PDAC cell lines impaired proliferation and anchorage independent growth supporting a role for mTORC2 in fully transformed cells. These data suggest that mTORC2 cooperates with activated KRAS in the initiation and progression of PanIN lesions and is required for the transformation and maintenance of PDAC. My work illustrates phenotypic differences between pancreatic loss of Rictor and PDK1 in the context of KRAS, broadens our understanding of this signaling node and suggests that mTORC2 may potentially be a viable target for PDAC therapies.

Orientador: Gabriel Forato Anhê
Tese (doutorado) - Universidade Estadual de Campinas, Faculdade de Ciências Médicas
Made available in DSpace on 2018-08-25T19:01:58Z (GMT). No. of bitstreams: 1 Araujo_ThiagoMatosFerreirade_D.pdf: 1239554 bytes, checksum: 87d5fc958173ca83a217021c9d866455 (MD5) Previous issue date: 2014
Resumo: A obesidade é caracterizada pela deposição ectópica de gordura no fígado. Este acúmulo de gordura hepática (NAFLD) pode gerar consequências graves, como a hepatite não alcoólica (NASH), fator de ricos para carcino hepatocelular (HCC). A morte de hepatócitos, evento chave na evolução da NAFLD para NASH, é causada pelo excesso de nutrientes e é dependente do estresse de retículo endoplasmático (RE). O estresse no RE resulta no acúmulo de proteínas não processadas desencadeia a "unfolded protein response" (UPR), podendo gerar apoptose. A mTOR é formada basicamente por dois complexos: mTOR1 e mTOR2; ambos são sensíveis a nutrientes, a insulina e a rapamicina. O complexo mTOR2/Rictor catalisa a fosforilação da AKT, aumentando a sinalização da insulina. Deste modo, o objetivo deste trabalho foi avaliar a relação entre ativação da mTOR, do estresse de RE e da apoptose em hepatócito expostos a ácidos graxos livres. Observamos que a apoptose causada pelo palmitato ativa o estresse de RE de maneira tempo dependente. Não observamos alterações na fosforilação de proteínas alvo específicas para o complexo mTOR1. No entanto, a fosforilação geral da mTOR foi estimulada pelo palmitato. Altas doses de rapamicina inibiram a apoptose e do estresse de RE causado pelo palmitato, sugerindo a participação do complexo mTOR2. Estes resultados ainda foram confirmados pelo silenciamento gênico da Rictor. A fosforilação em serina 473 da AKT apresenta um caráter transitório, elevando-se em tempos que precedem morte e o estresse de RE, e diminuindo em tempos prolongados concomitantemente à apoptose. A inibição da AKT pelo "AKT inhibitor" gerou diminuição da apoptose, do estresse de RE e da incorporação lipídica na linhagem de hepatoma. Estes dados sugerem que a AKT, como alvo preferencial da mTOR2 é necessária para geração de morte e da UPR. A glicose (33.3mM) gera morte as células HepG2 e esta é inibida com baixas doses de rapamicina, mostrando possível atividade via mTOR1 nesta resposta. De outro modo, a frutose (4.5mM) que também desencadeia apoptose das células de hepatoma, tem seu efeito inibido por doses maiores de rapamicina, indicando atividade mTOR2 neste processo. No entanto, a possibilidade de diferentes monossacarídeos recrutarem complexos diferentes de mTOR para desencadear apoptose ainda precisa ser melhor explorada
Abstract: Obesity is characterized by fat ectopic deposition in liver. This hepatic fat accumulation our non-alcoholic fat liver disease (NAFLD) can have serious consequences such as non-alcoholic hepatitis (NASH), that is a factor to liver cancer. The cell death of hepatocytes is an important event in the development to NAFLD to NASH, all that are caused by excess nutrients and dependent of endoplasmic reticulum (ER) stress. The ER stress is caused by accumulation of unfolded proteins triggers the unfolded protein response (UPR), which mau cause apoptosis. mTOR is basically formed by two complexes: mTOR1 and mTOR2, both are sensitive to nutrients, insulin and rapamycin. The mTOR2/Rictor complex catalyse AKT phosphorylation increasing the insulin pathway. All together, the aim of this study was evaluate the relationship between mTOR, ER stress and apoptosis in liver cells exposed to free fatty acids. We observed that apoptosis caused by palmitate activates ER stress in a manner dependent on time. We din¿t observed changes in phosphorylation of specific target proteins to mTOR1 complex. However, a general phosphorylation of mTOR was stimulated by palmitate. High doses of rapamycin inhibited apoptosis and ER stress caused by palmitate, suggesting the participation of the mTOR2 complex. These results were further confirmed by gene silencing of Rictor. The AKT phospholylation in serine 473 has a transitional character, rising in times that preceding cell death and ER stress, and decreasing concomitantly apoptosis in prolonged times. Inhibition of AKT by AKT inhibitor caused a decrease in apoptosis, ER stress and lipid incorporation in hepatoma cell line. These data suggest that AKT, preferential targets of mTOR2 is required for generation death and UPR. Glucose (33.3mM) generates HepG2 cell death and this is inhibited by low doses on rapamycin, showing possible mTOR1 activity. Otherwise, fructose (4.5mM) also triggers apoptosis of hepatoma cells; its effect is inhibited by higher doses of rapamycin, indicating mTOR2 activity in this process. However, the possibility of different monosaccharide recruit different complexes of mTOR to trigger apoptosis should be further explored
Doutorado
Farmacologia
Doutor em Farmacologia

Retinitis Pigmentosa (RP) is an inherited photoreceptor degenerative disease that leads to blindness and affects about 1 in 4000 people worldwide. The disease is predominantly caused by mutations in genes expressed exclusively in the night active rod photoreceptors; however, blindness results from the secondary loss of the day active cone photoreceptors, the mechanism of which remains elusive. Here, we show that the mammalian target of rapamycin complex 1 (mTORC1) is required to delay the progression of cone death during disease and that constitutive activation of mTORC1 is sufficient to maintain cone function and promote cone survival in RP. Activation of mTORC1 increased expression of genes that promote glucose uptake, retention and utilization, leading to increased NADPH levels; a key metabolite for cones. This protective effect was conserved in two mouse models of RP, indicating that the secondary loss of cones can be delayed by an approach that is independent of the primary mutation in rods. However, since mTORC1 is a negative regulator of autophagy, its constitutive activation led to an unwarranted secondary effect of shortage of amino acids due to incomplete digestion of autophagic cargo, which reduces the efficiency of cone survival over time. Moderate activation of mTORC1, which promotes expression of glycolytic genes, as well as maintains autophagy, provided more sustained cone survival. Together, our work addresses a long-standing question of non-autonomous cone death in RP and presents a novel, mutation-independent approach to extend vision in a disease that remains incurable.

Retinitis Pigmentosa (RP) is an inherited photoreceptor degenerative disease that leads to blindness and affects about 1 in 4000 people worldwide. The disease is predominantly caused by mutations in genes expressed exclusively in the night active rod photoreceptors; however, blindness results from the secondary loss of the day active cone photoreceptors, the mechanism of which remains elusive. Here, we show that the mammalian target of rapamycin complex 1 (mTORC1) is required to delay the progression of cone death during disease and that constitutive activation of mTORC1 is sufficient to maintain cone function and promote cone survival in RP. Activation of mTORC1 increased expression of genes that promote glucose uptake, retention and utilization, leading to increased NADPH levels; a key metabolite for cones. This protective effect was conserved in two mouse models of RP, indicating that the secondary loss of cones can be delayed by an approach that is independent of the primary mutation in rods. However, since mTORC1 is a negative regulator of autophagy, its constitutive activation led to an unwarranted secondary effect of shortage of amino acids due to incomplete digestion of autophagic cargo, which reduces the efficiency of cone survival over time. Moderate activation of mTORC1, which promotes expression of glycolytic genes, as well as maintains autophagy, provided more sustained cone survival. Together, our work addresses a long-standing question of non-autonomous cone death in RP and presents a novel, mutation-independent approach to extend vision in a disease that remains incurable.

Orientador: Jose Barreto Campello Carvalheira
Tese (doutorado) - Universidade Estadual de Campinas, Faculdade de Ciências Médicas
Made available in DSpace on 2018-08-25T02:56:20Z (GMT). No. of bitstreams: 1 Mendes_MariaCarolinaSantos_D.pdf: 2658779 bytes, checksum: 153ed5344815e7e59a41c04c4a965670 (MD5) Previous issue date: 2014
Resumo: A proteína mTOR é um proteína reguladora chave de vários processos celulares, dentre eles proliferação, crescimento e sobrevivência celular. Fatores de crescimento, oxigênio, status energético e a presença de aminoácidos são fundamentais para que todos esses processos ocorram normalmente. Descobertas realizadas nas últimas décadas mostraram que a via da mTOR encontra-se ativada em vários processos celulares, incluindo formação tumoral e angiogênese. A leucina é um aminoácido de cadeia ramificada que tem o maior potencial em ativar a via da mTOR. Devido sua capacidade de promover a síntese proteica e ganho de massa muscular, seu uso é constantemente estimulado em pacientes com câncer. No entanto, seus efeitos no crescimento tumoral não está claro. Dessa forma, realizamos um estudo cujo objetivo principal foi investigar os efeitos da dieta suplementada com leucina na modulação do crescimento tumoral em diferentes linhagens de células tumorais que se diferenciem em relação à ativação constitutiva da via IRS1/Akt/mTOR. Estudos in vivo e in vitro realizados demonstraram que as células que se diferenciam em relação à ativação da via IRS1/AKT/mTOR respondem de maneira distinta à suplementação com leucina. Linhagens de células tumorais que possuem a via da mTOR constitutivamente ativada, PC-3 e MCF-7, quando suplementadas com doses elevadas de leucina in vitro reduziram a proliferação celular e causaram retenção das células na fase G1 do ciclo celular. Já o xenoenxerto tumoral da PC-3 reduziu sua proliferação e aumentou a morte celular quando os animais foram suplementados com leucina na dieta. Nós também observamos aumento da atividade da mTOR e da p70S6K em todas as linhagens celulares quando suplementadas com leucina. O aumento da atividade da proteína mTOR foi acompanhado de redução na fosforilação de AKTser473 nas células que possuíam a via da PI3K hiperativada (PC-3 e MCF-7). Esse fato pode estar ocorrendo devido a ativação das alças de contraregulação ocasionadas pela estimulação excessiva provocada pela suplementação com leucina, naquelas linhagens celulares que já possuem a via hiperativada. Fato este comprovado pelo aumento da fosforilação em serina 307 da proteína IRS1. Dessa forma, nossos resultados sugerem que a ativação da via da mTOR é central para determinar a sensibilidade de tumores à dieta suplementada com leucina, podendo modular o desenvolvimento tumoral naquelas células que já possuem a via IRS1/AKT/mTOR constitutivamente ativada. O mecanismo pelo qual a leucina pode retardar o desenvolvimento tumoral em células que possuem a via da mTOR hiperativada parece estar relacionado com o eixo de regulação negativa p70S6K-PI3K, com consequente redução da fosforilação de AKT e liberação das vias apoptóticas nos tecidos tumorais
Abstract: mTOR is a key regulatory protein in various cellular processes including proliferation, cell growth and survival. Growth factors, oxygen, energy status and amino acids are all essential to these processes. New findings in the last few decades have shown that the mTOR pathway is activated in many cellular processes, including tumorigenesis and angiogenesis. The branched chain amino acid leucine has the greatest potential to activate the mTOR pathway. Due to its ability to promote protein synthesis and muscle mass gain, use of leucine is frequently utilized in patients with cancer. However, the effect of leucine on tumor growth is not clear. The aim of this study is therefore to investigate the effect of diet-supplemented leucine on the modulation of tumor growth in several tumor cell lines that differ in the constitutive activation status of the insulin receptor substrate 1 (IRS1)/AKT/mTOR pathway. Both in vitro and in vivo experiments demonstrated different cell proliferation responses when cells were exposed to high doses of leucine. Tumor cell lines PC-3 and MCF-7, which have a constitutively activated mTOR signaling, displayed reduced cell proliferation and G1 phase cell cycle arrest when supplemented with high doses of leucine in vitro. Likewise, leucine-supplemented PC-3 cell tumor xenografts displayed reduced proliferation and increased cell death. We also observed increased activity of mTOR and its downstream substrate p70S6K in all cell lines supplemented with leucine. Increased mTOR activity was accompanied by a reduction in AKT serine 473 (ser473) phosphorylation in cell lines with a hyperactivated PI3K pathway (PC-3 and MCF-7). This most likely occurred because leucine supplementation further increased mTOR and p70S6K activity, triggering the inhibitory p70S6K/IRS1 axis. In fact, we found increased IRS1 ser307 phosphorylation in hyperactivated cell lines (PC-3 and MCF-7) supplemented with high doses of leucine. Therefore, our results suggest that mTOR pathway activation is central to determining the sensitivity of tumors to leucine supplementation. Furthermore, this could affect the response to leucine-supplemented therapies of those tumors in which the PI3K pathway is constitutively activated. The mechanism for this appears to be related to the negative p70S6K/IRS1 regulation axis, with consequent reduction of AKT phosphorylation and the release of apoptotic pathways in tumor tissues
Doutorado
Fisiopatologia Médica
Doutora em Ciências

Recent studies suggest adipose tissue plays a critical role in regulating whole body energy homeostasis in both animals and humans. In particular, activating brown adipose tissue (BAT) activity is now appreciated as a potential therapeutic strategy against obesity and metabolic disease. However, the signaling circuits that coordinate nutrient uptake and BAT function are poorly understood. Here, I investigated the role of the nutrient-sensing mTOR signaling pathway in BAT by conditionally deleting Rictor, which encodes an essential component of mTOR Complex 2 (mTORC2) either in brown adipocyte precursors or mature brown adipocytes. In general, inhibiting BAT mTORC2 reduces glucose uptake and de novo lipogenesis pathways while increases lipid uptake and oxidation pathways indicating a switch in fuel utilization. Moreover, several key thermogenic factors (Ucp1, Pgc1α, and Irf4) are elevated in Rictor-deficient BAT, resulting in enhanced thermogenesis. Accordingly, mice with mTORC2 loss in BAT are protected from HFD-induced obesity and metabolic disease at thermoneutrality. In vitro culture experiments further suggest that mTORC2 cell-autonomously regulates the BAT thermogenic program, especially Ucp1 expression, which depends on FoxO1 activity. Mechanistically, mTORC2 appears to inhibit FoxO1 by facilitating its lysine-acetylation but not through the canonical AKT-mediated phosphorylation pathway. Finally, I also provide evidence that β-adrenergic signaling which normally triggers thermogenesis also induces FoxO1 deacetylation in BAT. Based on these data, I propose a model in which mTORC2 functions in BAT as a critical signaling hub for coordinating nutrient uptake, fuel utilization, and thermogenic gene expression. These data provide a foundation for future studies into the mTORC2-FoxO1 signaling axis in different metabolic tissues and physiological conditions.

Recent studies suggest adipose tissue plays a critical role in regulating whole body energy homeostasis in both animals and humans. In particular, activating brown adipose tissue (BAT) activity is now appreciated as a potential therapeutic strategy against obesity and metabolic disease. However, the signaling circuits that coordinate nutrient uptake and BAT function are poorly understood. Here, I investigated the role of the nutrient-sensing mTOR signaling pathway in BAT by conditionally deleting Rictor, which encodes an essential component of mTOR Complex 2 (mTORC2) either in brown adipocyte precursors or mature brown adipocytes. In general, inhibiting BAT mTORC2 reduces glucose uptake and de novo lipogenesis pathways while increases lipid uptake and oxidation pathways indicating a switch in fuel utilization. Moreover, several key thermogenic factors (Ucp1, Pgc1α, and Irf4) are elevated in Rictor-deficient BAT, resulting in enhanced thermogenesis. Accordingly, mice with mTORC2 loss in BAT are protected from HFD-induced obesity and metabolic disease at thermoneutrality. In vitro culture experiments further suggest that mTORC2 cell-autonomously regulates the BAT thermogenic program, especially Ucp1 expression, which depends on FoxO1 activity. Mechanistically, mTORC2 appears to inhibit FoxO1 by facilitating its lysine-acetylation but not through the canonical AKT-mediated phosphorylation pathway. Finally, I also provide evidence that β-adrenergic signaling which normally triggers thermogenesis also induces FoxO1 deacetylation in BAT. Based on these data, I propose a model in which mTORC2 functions in BAT as a critical signaling hub for coordinating nutrient uptake, fuel utilization, and thermogenic gene expression. These data provide a foundation for future studies into the mTORC2-FoxO1 signaling axis in different metabolic tissues and physiological conditions.

Saccharomyces cerevisiae, the budding yeast was long history as industrial baker’s yeast due to its ability to produce numerous product such as ethanol, acetate, industrial bakers etc. Interestingly, this yeast was also important tools for studying biological mechanism in eukaryotic cells including aging, autophagy, mitochondrial response etc. S. cerevisiae has arisen as a powerful chemical and genetic screening platform, due to a rapid workflow with experimental amenability and the availability of a wide range of genetic mutant libraries. Calorie restriction (CR) as the reduction of nutrients intake could promote yeast longevity through some pathways such as inhibition of nutrient sensing target of rapamycin (TOR), serine–threonine kinase (SCH9), protein adenylate cyclase (AC), protein kinase A (PKA) and ras, reduced ethanol, acetic acid and apoptotic process. In addition, CR also induces the expression of antioxidative proteins, sirtuin2 (Sir2), autophagy and induction of mitochondrial yeast adaptive response. Three methods, spotting test; chronological life span (CLS) and replicative life span (RLS) assays, have been developed to study aging in S. cerevisiae. Here, we present strategies for pharmacological anti-aging screens in yeast, discuss common pitfalls and summarize studies that have used yeast for drug discovery.